FCMV
Foresite Capital Management VI Portfolio holdings
AUM
$178M
This Quarter Return
-1.04%
1 Year Return
–
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$178M
AUM Growth
-$4.66M
(-2.6%)
Cap. Flow
+$10.9M
Cap. Flow
% of AUM
6.12%
Top 10 Holdings %
Top 10 Hldgs %
83.94%
Holding
20
New
6
Increased
2
Reduced
6
Closed
–
Top Buys
| 1 |
HNGE
Hinge Health, Inc.
HNGE
|
+$6.99M |
| 2 |
Verastem
VSTM
|
+$5.3M |
| 3 |
Xenon Pharmaceuticals
XENE
|
+$5.01M |
| 4 |
IDEAYA Biosciences
IDYA
|
+$3.04M |
| 5 |
Avidity Biosciences
RNA
|
+$1.14M |
Top Sells
| 1 |
Akero Therapeutics
AKRO
|
+$6.41M |
| 2 |
Structure Therapeutics
GPCR
|
+$4.36M |
| 3 |
Allogene Therapeutics
ALLO
|
+$647K |
| 4 |
CASI Pharmaceuticals
CASI
|
+$640K |
| 5 |
Cullinan Oncology
CGEM
|
+$305K |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
CG Oncology
CGON
$2.53B
| $57.8M | 32.47% |
2,221,474
| – | – |
|
|
CNTA
2
Centessa Pharmaceuticals
CNTA
$3.04B
| $16.5M | 9.26% |
1,253,379
| – | – |
|
|
3
Akero Therapeutics
AKRO
$3.59B
| $13.1M | 7.35% |
244,900
-120,100
| -33% | -$6.41M |
|
|
ALMS
4
Alumis Inc. Common Stock
ALMS
$447M
| $12.7M | 7.16% |
4,247,670
+45,000
| +1% | +$135K |
|
5
RAPT Therapeutics
RAPT
$234M
| $12.5M | 7.03% |
1,562,500
| – | – |
|
|
BCAX
6
Bicara Therapeutics Inc. Common Stock
BCAX
$651M
| $8.82M | 4.96% |
949,260
-740
| -0.1% | -$6.88K |
|
7
Edgewise Therapeutics
EWTX
$1.55B
| $7.67M | 4.31% |
585,000
| – | – |
|
|
HNGE
8
Hinge Health, Inc.
HNGE
$4.7B
| $6.99M | 3.93% |
+135,000
| New | +$6.99M |
|
9
Corvus Pharmaceuticals
CRVS
$442M
| $6.92M | 3.89% |
1,731,233
+150,000
| +9% | +$600K |
|
10
Kymera Therapeutics
KYMR
$3.11B
| $6.39M | 3.59% |
146,332
| – | – |
|
|
11
Verastem
VSTM
$608M
| $5.3M | 2.98% |
+1,276,520
| New | +$5.3M |
|
|
12
Xenon Pharmaceuticals
XENE
$2.86B
| $5.01M | 2.82% |
+160,000
| New | +$5.01M |
|
|
13
Cullinan Oncology
CGEM
$382M
| $4.47M | 2.51% |
594,025
-40,533
| -6% | -$305K |
|
|
14
Structure Therapeutics
GPCR
$1.2B
| $4.36M | 2.45% |
210,000
-210,000
| -50% | -$4.36M |
|
|
15
Allogene Therapeutics
ALLO
$260M
| $3.25M | 1.83% |
2,875,357
-572,918
| -17% | -$647K |
|
|
16
IDEAYA Biosciences
IDYA
$2.17B
| $3.04M | 1.71% |
+144,468
| New | +$3.04M |
|
|
17
Avidity Biosciences
RNA
$5.28B
| $1.14M | 0.64% |
+40,000
| New | +$1.14M |
|
18
Spyre Therapeutics
SYRE
$977M
| $1.05M | 0.59% |
+70,000
| New | +$1.05M |
|
|
19
CASI Pharmaceuticals
CASI
$36.6M
| $929K | 0.52% |
787,121
-542,262
| -41% | -$640K |
|
20
Viridian Therapeutics
VRDN
$1.6B
| $27.6K | 0.02% |
1,974
| – | – |
|